Atherosclerotic inflammation triggers osteogenic bone transformation in calcified and stenotic human aortic valves: Still a matter of debate

被引:16
作者
Anger, Thomas [1 ,2 ]
Carson, Walter [1 ]
Weyand, Michael [3 ]
Daniel, Werner G. [2 ]
Hoeher, Martin [1 ]
Garlichs, Christoph D. [2 ]
机构
[1] Klinikum Bayreuth, Ctr Med 2, Dept Cardiol, D-10195445 Bayreuth, Germany
[2] Univ Erlangen Nurnberg, Dept Cardiol, D-8520 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Ctr Cardiac Surg, D-8520 Erlangen, Germany
关键词
Gene-profil; Atherosclerotic inflammation; Aortic valve disease; Statins; Osteogenic bone transformation; BASE-LINE CHARACTERISTICS; COA REDUCTASE INHIBITOR; UP-REGULATION; ENDOTHELIAL-CELLS; RANDOMIZED-TRIAL; CD40; LIGAND; STENOSIS; PROGRESSION; EXPRESSION; CALCIFICATION;
D O I
10.1016/j.yexmp.2008.11.001
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Sclerotic calcification of the aortic valve is a common disease in advanced age. However, pathophysiologic processes leading to valve calcifications are poorly understood. Transformation of atherosclerotic triggers to osteogenic differentiation is controversially discussed and is thought as a trigger of bone transformation in end stage disease. This study focuses on the transcriptional gene-profiling of severe calcified stenotic human aortic valves to clarify the molecular basis of the pathophysiological process. We collected severely calcified and stenotic human aortic valves (CSAV) with (CSAV+, n=10) and without (CSAV-, n=10) at least 4 weeks of statin pre-treatment prior to valve replacement and investigated transcriptional steady-state gene-profiling by using micro array technique and GAPDH-adjusted PCR for confirmation. Results were compared with findings in non-sclerotic aortic valves: C (n=6). Various parameters of inflammation were significantly up regulated as compared to C: eotaxin3, monokine induced by gamma-interferon, vascular adhesion protein-1 (VAP-1), peroxisome proliferative activated receptor-a or transforming growth factorf beta 1 (TGF beta 1). Except for TGF beta 1 and VAP-1, statin pre-treatment neutralized altered gene expression. Genes of osteogenic bone transformation (tenascin C, bone sialoprotein, Cbfa1, Osteocalcin, Beta-catenin, Sox-and Cyclin-genes) were found unaltered in their expression in both, CSAV- or CSAV+ in comparison to C. This study shows continuing atherosclerotic inflammation on CSAV. Additionally, no evidence of initiated osteoblastic differentiation process was found. Pre-treatment of patients with statins partially neutralized the gene pattern of inflammation on the aortic valves. This suggests that there are potent benefits of statins on early development of inflammation on calcified aortic valves. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 51 条
[1]
Aikawa M, 2001, CIRCULATION, V103, P276
[2]
VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: Effects of statins [J].
Anger, Thomas ;
Pohle, Falk K. ;
Kandler, Lukas ;
Barthel, Thomas ;
Ensminger, Stephan M. ;
Fischlein, Theodor ;
Weyand, Michael ;
Stumpf, Christian ;
Daniel, Werner G. ;
Garlichs, Christoph D. .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2007, 83 (03) :435-442
[3]
Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor κB, and Egr-1 [J].
Bavendiek, U ;
Libby, P ;
Kilbride, M ;
Reynolds, R ;
Mackman, N ;
Schönbeck, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25032-25039
[4]
Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community [J].
Bellamy, MF ;
Pellikka, PA ;
Klarich, KW ;
Tajik, AJ ;
Enriquez-Sarano, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (10) :1723-1730
[5]
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation [J].
Caira, FC ;
Stock, SR ;
Gleason, TG ;
McGee, EC ;
Huang, J ;
Bonow, RO ;
Spelsberg, TC ;
McCarthy, PM ;
Rahimtoola, SH ;
Rajamannan, NM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) :1707-1712
[6]
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial [J].
Chan, Kwan-Leung ;
Teo, Koon ;
Tam, James ;
Dumesnil, Jean G. .
AMERICAN HEART JOURNAL, 2007, 153 (06) :925-931
[7]
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis [J].
Cowell, SJ ;
Newby, DE ;
Prescott, RJ ;
Bloomfield, P ;
Reid, J ;
Northridge, DB ;
Boon, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (23) :2389-2397
[8]
Freeman Rosario V, 2004, Expert Rev Cardiovasc Ther, V2, P107, DOI 10.1586/14779072.2.1.107
[9]
Spectrum of calcific aortic valve disease - Pathogenesis, disease progression, and treatment strategies [J].
Freeman, RV ;
Otto, CM .
CIRCULATION, 2005, 111 (24) :3316-3326
[10]
Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia [J].
Garlichs, CD ;
John, S ;
Schmeisser, A ;
Eskafi, S ;
Stumpf, C ;
Karl, M ;
Goppelt-Struebe, M ;
Schmieder, R ;
Daniel, WG .
CIRCULATION, 2001, 104 (20) :2395-2400